42 related articles for article (PubMed ID: 1710609)
1. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
2. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
[TBL] [Abstract][Full Text] [Related]
3. Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.
Fady C; Gardner A; Gera JF; Lichtenstein A
Cancer Immunol Immunother; 1993 May; 36(5):307-14. PubMed ID: 8097427
[TBL] [Abstract][Full Text] [Related]
4. Cytokine regulation of cell-to-cell interactions in lymphokine-activated killer cell cytotoxicity in vitro.
Takahashi T; Ishikura H; Iwai K; Takahashi C; Kato H; Tanabe T; Yoshiki T
Cancer Immunol Immunother; 1993; 36(2):76-82. PubMed ID: 8093857
[TBL] [Abstract][Full Text] [Related]
5. Investigating the lysis of small-cell lung cancer cell lines by activated natural killer (NK) cells with a fluorometric assay for NK-cell-mediated cytotoxicity.
Lehmann C; Glass B; Zeis M; Schmitz N; Uharek L
Cancer Immunol Immunother; 1999 Jul; 48(4):209-13. PubMed ID: 10431691
[TBL] [Abstract][Full Text] [Related]
6. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing.
Katsanis E; Bausero MA; Xu H; Orchard PJ; Xu Z; McIvor RS; Brian AA; Blazar BR
Cancer Immunol Immunother; 1994 Feb; 38(2):135-41. PubMed ID: 7905790
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.
Van de Vrie W; Van der Heyden SA; Gheuens EE; Bijma AM; De Bruijn EA; Marquet RL; Van Oosterom AT; Eggermont AM
Cancer Immunol Immunother; 1993 Oct; 37(5):337-42. PubMed ID: 8402737
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive effect of shedding intercellular adhesion molecule 1 antigen on cell-mediated cytotoxicity against tumor cells.
Koyama S
Jpn J Cancer Res; 1994 Feb; 85(2):131-4. PubMed ID: 7908284
[TBL] [Abstract][Full Text] [Related]
9. Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10.
Maio M; Gulwani B; Tombesi S; Ferrone S
Cancer Immunol Immunother; 1989; 30(1):34-42. PubMed ID: 2513111
[TBL] [Abstract][Full Text] [Related]
10. Increased ICAM-1 expression in transformed human oral epithelial cells: molecular mechanism and functional role in peripheral blood mononuclear cell adhesion and lymphokine-activated-killer cell cytotoxicity.
Huang GT; Zhang X; Park NH
Int J Oncol; 2000 Sep; 17(3):479-86. PubMed ID: 10938387
[TBL] [Abstract][Full Text] [Related]
11. Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.
Fady C; Gardner A; Gera JF; Lichtenstein A
Cancer Immunol Immunother; 1993 Oct; 37(5):329-36. PubMed ID: 8104695
[TBL] [Abstract][Full Text] [Related]
12. Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.
Avila-Cariño J; Torsteinsdottir S; Ehlin-Henriksson B; Masucci MG; Klein E
Cancer Immunol Immunother; 1991; 34(2):128-32. PubMed ID: 1722139
[TBL] [Abstract][Full Text] [Related]
13. Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells.
Chong AS; Markham PN; Gebel HM; Bines SD; Coon JS
Cancer Immunol Immunother; 1993; 36(2):133-9. PubMed ID: 8093856
[TBL] [Abstract][Full Text] [Related]
14. Human retinoblastoma: in vitro differentiation and immunoglobulin superfamily antigen modulation by retinoic acid.
Conway RM; Madigan MC; King NJ; Billson FA; Penfold PL
Cancer Immunol Immunother; 1997 Jun; 44(4):189-96. PubMed ID: 9222276
[TBL] [Abstract][Full Text] [Related]
15. The immunogenic properties of drug-resistant murine tumor cells do not correlate with expression of the MDR phenotype.
Killion JJ; Radinsky R; Dong Z; Fishbeck R; Whitworth P; Fidler IJ
Cancer Immunol Immunother; 1993 Jun; 36(6):381-6. PubMed ID: 8098991
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin induced resistance of sensitive K 562 cells to natural killer lymphocyte attack.
Benoist H; Madoulet C; Jardillier JC; Desplaces A
Cancer Immunol Immunother; 1985; 20(2):122-8. PubMed ID: 3862464
[TBL] [Abstract][Full Text] [Related]
17. Differential growth inhibition and enhancement of major histocompatibility complex class I antigen expression by interferons in a small-cell lung cancer cell line and its doxorubicin-selected multidrug-resistant variant.
Cole SP; Campigotto BM; Johnson JG; Elliott BE
Cancer Immunol Immunother; 1991; 33(4):274-7. PubMed ID: 1711927
[TBL] [Abstract][Full Text] [Related]
18. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.
Castella B; Vitale C; Coscia M; Massaia M
Cell Mol Life Sci; 2011 Jul; 68(14):2419-32. PubMed ID: 21584812
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of multidrug resistance by L1210 leukemia cells decreases their tumorigenicity and enhances their susceptibility to the host immune response.
Martín-Orozco E; Ferragut JA; Garcia-Peñarrubia P; Ferrer-Montiel A
Cancer Immunol Immunother; 2005 Apr; 54(4):328-36. PubMed ID: 15692844
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
